Microsoft Word - MDA Q4-2563_Eng_28 may 2020 May 27, 2020 Subject Management Discussion and Analysis for the year ended 31st March 2020 To President of the Stock Exchange of Thailand Secretary of the
total value of consideration criterion which granted the highest result, referenced from the consolidated audited financial statement of the Company ended March 31, 2019. After the computation of the
“Company”) would like to clarify in operating performance for the 1st quarter (three months period) ended March 31, 2018. The Company’s net profit was Baht 68.87 Million which decreased Baht 32.04 Million or
22 February 2019 Please find below the additional information supporting our financial statements for period ended December 31, 2018. Total revenues decreased slightly to THB 1,132 million from THB
Manager of the Stock Exchange of Thailand For the Q3/2019 period ended of September 30, 2019 (9 months) operating result of the company net loss Baht 0.22 Million comparison with the previous Q3/2018’s net
(the “Company”) would like to clarify in operating performance of year 2019 ended December 31st 2019. The Company’s net profit was Baht 133.38 Million which increased Baht 27.83 Million or 26.37
the year ended December 31, 2019 To Director and Manager the Stock Exchange of Thailand According to the Board of Directors’ Meeting No.2/ 2 0 2 0 of DOD Biotech Public Company Limited ( “ the Company
หนังสือแสดงการรับทราบความผิด 27 February 2020 Subject : Management Discussion and Analysis of the year ended 31 December 2019 Attn. : Director and Manager The Stock Exchange of Thailand Encls. : A
At Hor-For 0126/2550 August 8th, 2017 At Hor-For 0101/2560 Subject Notification of the performance of 2nd quarter ended June 30, 2017 Attn Directors and Manager, The Stock Exchange of Thailand We
“Company”) would like to clarify in operating performance for the 2nd quarter (three months period) ended June 30, 2017. The Company’s net profit was Baht 12.56 Million which decreased Baht 91.21 Million or